Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Creutzfeldt-Jakob disease in United Kingdom patients treated with human pituitary growth hormone.

Neurology - 23 Sept 2003

Swerdlow A J, Higgins C D, Adlard P, Jones M E, Preece M A

Abstract excerpt

OBJECTIVE: To investigate risk factors for Creutzfeldt-Jakob disease (CJD) in patients in the United Kingdom treated with human pituitary growth hormone (hGH). METHODS: Incidence rates of CJD, based on person-year denominators, were assessed in a cohort of 1,848 patients treated with hGH in the United Kingdom from 1959 through 1985 and followed to the end of 2000. RESULTS: CJD developed in 38 patients. Risk of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chromatography, Gel
Share to Creutzfeldt-Jakob Syndrome
Share to Databases, Factual

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Dwarfism, Pituitary

Share to Human Growth Hormone

Share to Hypopituitarism

Share to Pituitary Gland

Share to Prions

Source

Identifiers

PMID: 14504321
DOI: 10.1212/01.wnl.0000084000.27403.15

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Creutzfeldt-Jakob disease in United Kingdom patients treated with human pituitary growth hormone.PMID 14504321Read ↗

Iatrogenic Creutzfeldt-Jakob disease.Semantic proximity Read ↗

UK Iatrogenic Creutzfeldt-Jakob disease: investigating human prion transmission across genotypic barriers using human tissue-based and molecular approaches.Semantic proximity Read ↗

Iatrogenic CJD due to pituitary-derived growth hormone with genetically determined incubation times of up to 40 years.Semantic proximity Read ↗

Creutzfeldt-Jakob disease in the United States, 1979-1994: using national mortality data to assess the possible occurrence of variant cases.Semantic proximity Read ↗

Genetic predisposition to iatrogenic Creutzfeldt-Jakob disease.Semantic proximity Read ↗

Descriptive epidemiology of Creutzfeldt-Jakob disease in six European countries, 1993-1995. EU Collaborative Study Group for CJD.Semantic proximity Read ↗

Distinct pathological phenotypes of Creutzfeldt-Jakob disease in recipients of prion-contaminated growth hormone.Semantic proximity Read ↗

[Phenotype and incidence of Creutzfeldt-Jakob disease in Finland in 1997-2013].Semantic proximity Read ↗

Iatrogenic Alzheimer’s disease in recipients of cadaveric pituitary-derived growth hormoneSemantic proximity Read ↗

The spectrum of safety: variant Creutzfeldt-Jakob disease in the United Kingdom.Semantic proximity Read ↗

Creutzfeldt-Jakob disease and related diseases in France from 1998 to 2000.Semantic proximity Read ↗

Creutzfeldt-Jakob disease after pituitary-derived human growth hormone therapy: two cases with valine 129 homozygous genotype.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.